Gathering onco-hematological laboratories, research centers, and industrial and institutional partners, the nonprofit VidjilNet consortium is dedicated to:
Being a member of VidjilNet is an opportunity to participate in a community of professionals in hematology, immunology, oncology, and bioinformatics and to promote open research. Members have the chance to contribute to shaping and enhancing the Vidjil platform, fostering a collaborative effort that aligns with their specific requirements. VidjilNet emphasizes the importance of continuous learning and skill development, empowering their teams with the knowledge needed to optimize their research or clinical endeavors.
The consortium works into a quality approach concerning both software development and testing, the relationship with its members, and ethics on health data processing. Vidjil was awarded an honorable mention at the 2022 Open Science Awards for Open Source Research Software, in the Community category.
VidjilNet is incubated in Inria since 2018, and membership is offered since the end of 2019.
Minimal Membership 3 075 € / year
Standard Membership (Laboratory) 10 248 € / year
Shared, Industrial, or Support Membership 25 620 € / year
Support for 150 other clinical samples 3 075 €
Support for 1500 other clinical samples 20 496 €
fees are before VAT
2024 workshop took place in Rennes on 22-23 May 2024.
Some of the slides and video captures are now available on the workshop page.
Next session will be held in 18 months.
Feature tour - Open monthly meeting on Thursdays
Each month, discover Vidjil features during a 15’ talk. Join us at zoom link
Feature tour - Open monthly meeting on Thursdays
2023 General Assembly The consortium Plenary Assembly 2023 was held on 5 December 2023.
Bilateral meetings can also be arranged.
The VidjilNet consortium is run by an Executive Committee and a Scientific and Technical Committee. Each committee gather 3 elected members, 3 representatives of the developers, and 1 representative of Inria.
Members
Developers
Inria
Users
Developers
Inria
The Vidjil methods and platform were first described in [Giraud, Salson 2014] (algorithm) and [Duez 2016] (web platform). Reference for protocols are [Villarese 2022] (marker identification in ALL) and [Septenville 2022] (assessment of mutational status in CLL).
More than 40 studies in hematology, immunology, and/or computational biology were published using the Vidjil platform, including 20+ articles involving VidjilNet developers and researchers.